Biopharmaceutical News and Research

RSS

Results of post-mortem brain tissue study using Navidea's NAV4694 imaging agent presented at AAIC 2013

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that researchers at McGill Center for Studies in Aging, Douglas Research Institute and Montreal Neurological Institute presented results of a post-mortem brain tissue study using Navidea's investigational Fluorine-18 labeled β-amyloid imaging agent, NAV4694, during the Alzheimer's Association International Conference in Boston, MA.

23 Jul 2013

GW Pharmaceuticals to expand marketing authorization for Sativex to France

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has submitted an application under the European Mutual Recognition Procedure seeking to expand the marketing authorization for Sativex into France for the treatment of spasticity due to Multiple Sclerosis.

22 Jul 2013

Moberg Pharma granted exclusive rights to market Kerasal Nail in China

Moberg Pharma AB today announced that Menarini Asia-Pacific, a member of the Menarini Group - a top 40 global pharmaceutical company - has been granted the exclusive rights to market and sell Kerasal Nail in China. The companies now intend to seek marketing authorization for the product in the Chinese market.

22 Jul 2013

Tianyin Pharmaceutical provides further updates on Gingko Mihuan Oral Liquid

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients today provided further updates on the business development of its flagship product: Gingko Mihuan Oral Liquid with the SFDA approval number: H20013079.

19 Jul 2013

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the potential to modulate targets typically addressed by biologics, today announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals, Inc., the global biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders.

18 Jul 2013

Kolltan signs research agreement with CHOP for novel therapeutic approaches for neuroblastoma

Kolltan Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced a license and research agreement with The Children's Hospital of Philadelphia to commence a collaboration with Yaël Mossé, M.D, an internationally recognized clinician and scientist for her work studying the causes and novel therapeutic approaches for the treatment of children diagnosed with neuroblastoma.

18 Jul 2013

Quest Diagnostics completes sale of ibrutinib commercialization rights to Royalty Pharma

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today that it has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, for $485 million in cash.

From Quest Diagnostics 18 Jul 2013

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems.

17 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

London research fellow says clinical study reports and trial results should be shared publicly

Ben Goldacre, research fellow at the London School of Hygiene and Tropical Medicine, says we need all the evidence to make informed decisions about medicines.

12 Jul 2013

Creating a value development plan should be at the forefront of biopharmaceutical market

Mitch DeKoven, Director, HEOR, Real-World Evidence Solutions, IMS Health Inc. and Won Chan Lee, Ph.D., Principal, Health Economics and Outcomes Research, IMS Health, Inc. will present Optimizing Strategic Direction with Systematic Value Development at the Pharmaceutical Market Access Pricing and Reimbursement Conference in San Francisco on October 29, 2013.

11 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

ERYTECH, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia.

4 Jul 2013

Imaxio receives FP7 grant to support the development of S. aureus vaccine

Imaxio, a biopharmaceutical company specialized in vaccines, together with its partners from the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems, is pleased to announce today a European Union award of EUR 5.5 million to support the ‘Bellerophon Project’ consortium to develop a vaccine against Staphylococcus aureus (S. aureus).

3 Jul 2013

Sartorius launches new Sartocheck 4 plus Bag tester

Sartorius Stedim Biotech (SSB), a leading international equipment supplier for the pharma and biotech industries, has launched the new Sartocheck 4 plus Bag tester, the latest addition to its well-established Sartocheck line.

From Sartorius 3 Jul 2013

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Soligenix, Inc. (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

1 Jul 2013

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira, the world's leading provider of injectable drugs and infusion technologies, today received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use, recommending the European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

28 Jun 2013

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today positive topline clinical results from a 6-week randomized, double-masked, placebo-controlled Phase 1b/2a study of EBI-005 in patients with dry eye disease.

28 Jun 2013

Dassault Systèmes launches industry solution experience for pharmaceutical, biotech companies

Dassault Systèmes, the 3DEXPERIENCE Company, a world leader in 3D design, 3D Digital Mock Up and Product Lifecycle Management solutions, announced today the launch of a new industry solution experience for pharmaceutical and biotech companies, "Licensed to Cure for BioPharma."

27 Jun 2013

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women

Sprout Pharmaceuticals, the Raleigh-based pharmaceutical company developing flibanserin, a treatment being evaluated for Hypoactive Sexual Desire Disorder in pre-menopausal women, confirmed today that the company has resubmitted the New Drug Application for flibanserin earlier this year and expects US Food and Drug Agency action before the end of 2013.